Literature DB >> 15809762

Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells.

Janaína Fernandes1, Clovis Orlando da Fonseca, Anselmo Teixeira, Cerli Rocha Gattass.   

Abstract

Standard treatment of glioblastoma multiforme consisting of surgical resection, radiation and/or chemotherapy is rarely curative, emphasizing the need for new chemotherapeutic drugs. The monoterpene perillyl alcohol (POH) has preventive and therapeutic effects in a wide variety of pre-clinical tumor models and is currently under phase I and II clinical trials. In the present study, we analyzed its effect on human glioblastoma cell lines (U87 and A172) and a primary cell culture derived from a human glioblastoma tumor specimen (GBM-1). Using MTT, we showed that POH inhibits the viability of glioblastomas in a concentration-dependent way. Glioblastoma cell lines treated with POH showed morphological alterations characteristic of apoptosis. Analysis of cell cycle and quantification of DNA fragmentation, in cells stained with propidium iodide (PI), confirmed the apoptotic effect of POH on glioblastomas. These data support the potential usefulness of perillyl alcohol as an effective chemotherapeutic agent for patients with recurrent glioblastoma multiforme.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809762

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor.

Authors:  Diogo G Garcia; Lidia M F Amorim; Mauro V de Castro Faria; Aline S Freire; Ricardo E Santelli; Clóvis O Da Fonseca; Thereza Quirico-Santos; Patricia Burth
Journal:  Mol Cell Biochem       Date:  2010-08-06       Impact factor: 3.396

3.  Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.

Authors:  Juliana de Saldanha da Gama Fischer; Paulo Costa Carvalho; Clovis Orlando da Fonseca; Lujian Liao; Wim M Degrave; Maria da Gloria da Costa Carvalho; John R Yates; Gilberto B Domont
Journal:  J Proteome Res       Date:  2010-09-27       Impact factor: 4.466

Review 4.  Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities.

Authors:  Daniel E Morales; Shaker Mousa
Journal:  Heliyon       Date:  2022-05-22

5.  Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol.

Authors:  Juliana de Saldanha da Gama Fischer; Lujian Liao; Paulo C Carvalho; Valmir C Barbosa; Gilberto B Domont; Maria da Gloria da Costa Carvalho; John R Yates
Journal:  J Proteomics       Date:  2010-01-18       Impact factor: 4.044

Review 6.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

Authors:  Hui-Wen Lo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

7.  Essential oils for blood-brain barrier disruption: Preclinical studies of NEO100 in breast cancer brain metastases.

Authors:  Rimas V Lukas
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

8.  Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.

Authors:  Diogo Gomes Garcia; Hugo Caire de Castro-Faria-Neto; Camila Ignácio da Silva; Kauê Francisco Correa de Souza e Souza; Cassiano Felippe Gonçalves-de-Albuquerque; Adriana Ribeiro Silva; Lidia Maria da Fonte de Amorim; Aline Soares Freire; Ricardo Erthal Santelli; Luan Pereira Diniz; Flávia Carvalho Alcantara Gomes; Mauro Velho de Castro Faria; Patrícia Burth
Journal:  Mol Cancer       Date:  2015-05-15       Impact factor: 27.401

9.  Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.

Authors:  Clovis Orlando da Fonseca; Rafael Linden; Débora Futuro; Cerli Rocha Gattass; Thereza Quirico-Santos
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-07-29       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.